AYTU - Aytu BioScience: The Moonshot Continues To Orbit Awaiting The Next Giant Steps

• Initial details from the FDA-approved trial for the Healight medical device published by Cedars-Sinai show that UVA therapy may be a safe and effective treatment for severe SARS-CoV-2 infection.
• Cedars-Sinai and Aytu BioScience are working with the FDA to confirm the next steps on the advancement of this technology, including a more comprehensive trial and possibly an Emergency Use Authorization.
• Solid progress advancing the promising Healight technology and the highly-anticipated merger confirmation with Neos Therapeutics expected on March 18th should help propel Aytu's share price to a more rational valuation.

For further details see: